Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

CCR5 status and metastatic progression in colorectal cancer.

Suarez-Carmona M, Chaorentong P, Kather JN, Rothenheber R, Ahmed A, Berthel A, Heinzelmann A, Moraleda R, Valous NA, Kosaloglu Z, Eurich R, Wolf J, Grauling-Halama S, Hundemer M, Lasitschka F, Klupp F, Kahlert C, Ulrich A, Schneider M, Falk C, Jäger D, Zoernig I, Halama N.

Oncoimmunology. 2019 Jul 13;8(9):e1626193. doi: 10.1080/2162402X.2019.1626193. eCollection 2019.

2.

E3 ubiquitin ligase Smurf2: a prognostic factor in microsatellite stable colorectal cancer.

Klupp F, Giese C, Halama N, Franz C, Lasitschka F, Warth A, Schmidt T, Kloor M, Ulrich A, Schneider M.

Cancer Manag Res. 2019 Feb 22;11:1795-1803. doi: 10.2147/CMAR.S178111. eCollection 2019.

3.

High-Throughput Screening of Combinatorial Immunotherapies with Patient-Specific In Silico Models of Metastatic Colorectal Cancer.

Kather JN, Charoentong P, Suarez-Carmona M, Herpel E, Klupp F, Ulrich A, Schneider M, Zoernig I, Luedde T, Jaeger D, Poleszczuk J, Halama N.

Cancer Res. 2018 Sep 1;78(17):5155-5163. doi: 10.1158/0008-5472.CAN-18-1126. Epub 2018 Jul 2.

4.

In Silico Modeling of Immunotherapy and Stroma-Targeting Therapies in Human Colorectal Cancer.

Kather JN, Poleszczuk J, Suarez-Carmona M, Krisam J, Charoentong P, Valous NA, Weis CA, Tavernar L, Leiss F, Herpel E, Klupp F, Ulrich A, Schneider M, Marx A, Jäger D, Halama N.

Cancer Res. 2017 Nov 15;77(22):6442-6452. doi: 10.1158/0008-5472.CAN-17-2006. Epub 2017 Sep 18.

5.

Detailed resolution analysis reveals spatial T cell heterogeneity in the invasive margin of colorectal cancer liver metastases associated with improved survival.

Berthel A, Zoernig I, Valous NA, Kahlert C, Klupp F, Ulrich A, Weitz J, Jaeger D, Halama N.

Oncoimmunology. 2017 Feb 23;6(3):e1286436. doi: 10.1080/2162402X.2017.1286436. eCollection 2017.

6.

Serum MMP7, MMP10 and MMP12 level as negative prognostic markers in colon cancer patients.

Klupp F, Neumann L, Kahlert C, Diers J, Halama N, Franz C, Schmidt T, Koch M, Weitz J, Schneider M, Ulrich A.

BMC Cancer. 2016 Jul 18;16:494. doi: 10.1186/s12885-016-2515-7.

7.

Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients.

Halama N, Zoernig I, Berthel A, Kahlert C, Klupp F, Suarez-Carmona M, Suetterlin T, Brand K, Krauss J, Lasitschka F, Lerchl T, Luckner-Minden C, Ulrich A, Koch M, Weitz J, Schneider M, Buechler MW, Zitvogel L, Herrmann T, Benner A, Kunz C, Luecke S, Springfeld C, Grabe N, Falk CS, Jaeger D.

Cancer Cell. 2016 Apr 11;29(4):587-601. doi: 10.1016/j.ccell.2016.03.005.

8.

Expressional STAT3/STAT5 Ratio is an Independent Prognostic Marker in Colon Carcinoma.

Klupp F, Diers J, Kahlert C, Neumann L, Halama N, Franz C, Schmidt T, Lasitschka F, Warth A, Weitz J, Koch M, Schneider M, Ulrich A.

Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1548-55. doi: 10.1245/s10434-015-4485-4. Epub 2015 Mar 13.

PMID:
25773877
9.

Prognostic impact of a compartment-specific angiogenic marker profile in patients with pancreatic cancer.

Kahlert C, Fiala M, Musso G, Halama N, Keim S, Mazzone M, Lasitschka F, Pecqueux M, Klupp F, Schmidt T, Rahbari N, Schölch S, Pilarsky C, Ulrich A, Schneider M, Weitz J, Koch M.

Oncotarget. 2014 Dec 30;5(24):12978-89.

10.

Tumour-site-dependent expression profile of angiogenic factors in tumour-associated stroma of primary colorectal cancer and metastases.

Kahlert C, Pecqueux M, Halama N, Dienemann H, Muley T, Pfannschmidt J, Lasitschka F, Klupp F, Schmidt T, Rahbari N, Reissfelder C, Kunz C, Benner A, Falk C, Weitz J, Koch M.

Br J Cancer. 2014 Jan 21;110(2):441-9. doi: 10.1038/bjc.2013.745. Epub 2013 Nov 28.

11.

Hepatic metastases of colorectal cancer are rather homogeneous but differ from primary lesions in terms of immune cell infiltration.

Halama N, Spille A, Lerchl T, Brand K, Herpel E, Welte S, Keim S, Lahrmann B, Klupp F, Kahlert C, Weitz J, Grabe N, Jaeger D, Zoernig I.

Oncoimmunology. 2013 Apr 1;2(4):e24116.

12.

Expression analysis of aldehyde dehydrogenase 1A1 (ALDH1A1) in colon and rectal cancer in association with prognosis and response to chemotherapy.

Kahlert C, Gaitzsch E, Steinert G, Mogler C, Herpel E, Hoffmeister M, Jansen L, Benner A, Brenner H, Chang-Claude J, Rahbari N, Schmidt T, Klupp F, Grabe N, Lahrmann B, Koch M, Halama N, Büchler M, Weitz J.

Ann Surg Oncol. 2012 Dec;19(13):4193-201. doi: 10.1245/s10434-012-2518-9. Epub 2012 Aug 10.

PMID:
22878609
13.

Overexpression of ZEB2 at the invasion front of colorectal cancer is an independent prognostic marker and regulates tumor invasion in vitro.

Kahlert C, Lahes S, Radhakrishnan P, Dutta S, Mogler C, Herpel E, Brand K, Steinert G, Schneider M, Mollenhauer M, Reissfelder C, Klupp F, Fritzmann J, Wunder C, Benner A, Kloor M, Huth C, Contin P, Ulrich A, Koch M, Weitz J.

Clin Cancer Res. 2011 Dec 15;17(24):7654-63. doi: 10.1158/1078-0432.CCR-10-2816. Epub 2011 Oct 31.

14.

Invasion front-specific expression and prognostic significance of microRNA in colorectal liver metastases.

Kahlert C, Klupp F, Brand K, Lasitschka F, Diederichs S, Kirchberg J, Rahbari N, Dutta S, Bork U, Fritzmann J, Reissfelder C, Koch M, Weitz J.

Cancer Sci. 2011 Oct;102(10):1799-807. doi: 10.1111/j.1349-7006.2011.02023.x. Epub 2011 Aug 4.

Supplemental Content

Support Center